Search for New Genetic Mutations Major Effect in Crohn's Disease

Crohn Disease Clinical Trial

— MC-WES  

Official title:

Search for New Genetic Mutations Major Effect in Crohn's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02851134
• Other study ID #: 2013_53
• Secondary ID: 2014-A00023-44
• Status: Completed
• Start date: April 2015
• Est. completion date: April 2018

Study information

• Verified date: February 2019
• Source: University Hospital, Lille
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study highlight genetics mutations with major effect in Crohn's Disease (CD) by WES in individuals affected and healthy individuals from EPIMAD Inserm InVS registry families.

Description:

The EPIMAD Registry covers a large area of Northern France (9 millions inhabitants) and collects all incident CD cases and data from CD multiplex families (families with 3 or more CD affected patients) in the Nord the Pas de Calais the Somme and the Seine Maritime. If the investigators could demonstrate that most CD cases from multiplex families were related to high frequency of NOD2 gene mutations, the investigators found some CD multiplex families without any NOD2 gene involvement. Thus in these families high prevalence of CD cases may rely on other major genetic susceptibility variant(s) that remain to be determined.

this clinical research Whole Exome Sequencing protocol, aiming to highlight genetics mutations with major effect in CD has been initiated.

This study is a familial genetic study with intra-familial controls. The genetics analyses are:

• Ascertain of no significant NOD2 mutation in the family members by Sanger DNA sequencing

• WES (CD patients and family controls unaffected subjects)

• Genotyping of all mutations found, case control and segregation analyses to validate their implication in CD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 80 Years

Eligibility

Inclusion Criteria:

• Crohn disease subject

• EPIMAD family with, at least, 3 Crohn disease subjects

Exclusion Criteria:

• Pregnant or lactating women

Related Conditions & MeSH terms

• Crohn Disease

Intervention

Genetic:
• genetic analysis
genetic (Whole Exome Sequencing )

Biological:
• blood and stools samples
biological collection

Locations

Country	Name	City	State
France	CHRU, Hôpital Claude Huriez	Lille

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

References & Publications (1)

Frade-Proud'Hon-Clerc S, Smol T, Frenois F, Sand O, Vaillant E, Dhennin V, Bonnefond A, Froguel P, Fumery M, Guillon-Dellac N, Gower-Rousseau C, Vasseur F. A Novel Rare Missense Variation of the NOD2 Gene: Evidencesof Implication in Crohn's Disease. Int J — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NOD2 gene status	One of the main inclusion criteria is the absence in the family (and thus in the proband) of any NOD2 mutation that could be related with the high occurrence of Crohn's Disease in the family. So verification of the lack of CD related NOD2 gene mutation is a prerequisite to the inclusion of the family in the protocol. This is achieved by Sanger sequencing of all exons, exon-intron junctions and search for already described intronic mutations in the family proband.	8 months after recruiting
Secondary	Whole Exome Sequencing	Whole Exome Sequencing will be performed in every subject from all families. All genetic variants will be filtered with bioinformatic tools. Genetic variants with putative biological effect, presents in affected CD patients and absents in their unaffected relatives will be further investigated (i.e. cosegregation with the disease, involvement in a given pathway....). This study remains a "pilot study" to identify genetic variants that may be involved in Crohn's Disease.	10 months after recruiting